PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund

OXFORD, England, March 21, 2012 /PRNewswire/ --

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index's largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Francesco De Rubertis of Index Ventures, Dr Moncef Slaoui, Chairman of R&D at GSK and Dr Paul Stoffels, Worldwide Chairman of Johnson & Johnson Pharmaceuticals describe how the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund.

Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals^® (http://www.pharmadeals.net), containing over 43,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions.

Our Services Cover:

• Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
• Licensing (In and Out licensing)
• M&A (Companies & Assets)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

PharmaVentures' subsidiary, PharmaTelevision®, is the world's first dedicated online pharmaceutical television channel (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals®, PharmaTelevision® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:
Fintan Walton
CEO
PharmaVentures
+44 1865 332700
enquiries@pharmaventures.com